It's always important to assess the quality, efficacy and safety of a product before it's approved. Health Canada continues to review the antiviral drug molnupiravir for the treatment of COVID‑19.
On June 8th, 2022. See this statement in context.
On June 8th, 2022. See this statement in context.
June 8th, 2022 / 5:15 p.m.
Deputy Minister, Department of Health
It's always important to assess the quality, efficacy and safety of a product before it's approved. Health Canada continues to review the antiviral drug molnupiravir for the treatment of COVID‑19.
See context to find out what was said next.